Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency

Next Previous
Search
Trial Profile

A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Fludrocortisone; Hydrocortisone
  • Indications Congenital adrenal hyperplasia
  • Focus Therapeutic Use
  • Acronyms ARCH

    • Most Recent Events

    • 30 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 17 Nov 2020 Planned End Date changed from 1 Aug 2024 to 1 Jan 2026.
    • 17 Nov 2020 Planned primary completion date changed from 1 Aug 2024 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top